MYC rearrangement + BCL2 rearrangement
|
Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Lymphoma
|
venetoclax + DUP 785 Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
venetoclax + DUP 785 Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
cytarabine + methotrexate Resistant: C3 – Early Trials
|
cytarabine + methotrexate Resistant: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
rituximab Resistant: C3 – Early Trials
|
rituximab Resistant: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Lymphoma
|
lisocabtagene maraleucel Sensitive: C3 – Early Trials
|
lisocabtagene maraleucel Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
NHL
|
MYC rearrangement + BCL2 rearrangement
|
NHL
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
Follicular Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Follicular Lymphoma
|
EPOCH-R Sensitive: C3 – Early Trials
|
EPOCH-R Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
Follicular Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Follicular Lymphoma
|
R-DHAP Sensitive: C3 – Early Trials
|
R-DHAP Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lenalidomide + zanubrutinib Sensitive: C3 – Early Trials
|
lenalidomide + zanubrutinib Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
loncastuximab tesirine Sensitive: C3 – Early Trials
|
loncastuximab tesirine Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
C-RICE Sensitive: C3 – Early Trials
|
C-RICE Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
IACS-010759 Sensitive: D – Preclinical
|
IACS-010759 Sensitive: D – Preclinical
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
ibrutinib Resistant: D – Preclinical
|
ibrutinib Resistant: D – Preclinical
|
MYC rearrangement + BCL2 rearrangement
|
NHL
|
MYC rearrangement + BCL2 rearrangement
|
NHL
|
ibrutinib + alemtuzumab Sensitive: D – Preclinical
|
ibrutinib + alemtuzumab Sensitive: D – Preclinical
|
MYC rearrangement + BCL2 rearrangement
|
Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Lymphoma
|
HZX-02-059 Sensitive: D – Preclinical
|
HZX-02-059 Sensitive: D – Preclinical
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
venetoclax Sensitive: D – Preclinical
|
venetoclax Sensitive: D – Preclinical
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
|
copanlisib Sensitive: D – Preclinical
|
copanlisib Sensitive: D – Preclinical
|